168 related articles for article (PubMed ID: 26615131)
1. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Liu S; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):863-75. PubMed ID: 26615131
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.
Liu S; Kurzrock R
Cancer Treat Rev; 2014 Aug; 40(7):883-91. PubMed ID: 24867380
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
4. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
5. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
6. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
7. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
8. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
9. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
Dienstmann R; Braña I; Rodon J; Tabernero J
Oncologist; 2011; 16(12):1729-40. PubMed ID: 22135123
[TBL] [Abstract][Full Text] [Related]
10. Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
Dy GK; Adjei AA
CA Cancer J Clin; 2013; 63(4):249-79. PubMed ID: 23716430
[TBL] [Abstract][Full Text] [Related]
11. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of molecular-targeted drug therapy.
Le DL; Cao H; Yang LX
Anticancer Res; 2014 Jul; 34(7):3243-9. PubMed ID: 24982327
[TBL] [Abstract][Full Text] [Related]
13. [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
Grellety T; Brugères-Chakiba C; Chaminade A; Roubaud G; Ravaud A; Gross-Goupil M
Bull Cancer; 2014 Jun; 101(6):608-18. PubMed ID: 24977449
[TBL] [Abstract][Full Text] [Related]
14. Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME; Boerner SA; Lorusso PM
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
[TBL] [Abstract][Full Text] [Related]
15. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
16. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
[TBL] [Abstract][Full Text] [Related]
17. Optic and otic side effects of molecular targeted therapies.
O'Leary C
Semin Oncol Nurs; 2014 Aug; 30(3):169-74. PubMed ID: 25085028
[TBL] [Abstract][Full Text] [Related]
18. [Drug-related exanthema under immunotherapy and targeted oncological therapy].
Ziemer M; Livingstone E
Dermatologie (Heidelb); 2024 Jun; 75(6):440-450. PubMed ID: 38772932
[TBL] [Abstract][Full Text] [Related]
19. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Ho WL; Wong H; Yau T
Acta Ophthalmol; 2013 Nov; 91(7):604-9. PubMed ID: 22970709
[TBL] [Abstract][Full Text] [Related]
20. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
Fischer-Cartlidge EA
Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
